IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
about
Recent advances in subtyping tumors of the central nervous system using molecular data.Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patientsA combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.IDH-1R132H mutation status in diffuse glioma patients: implications for classificationMultiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastomaLong-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaThe Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.Anaplastic astrocytoma.The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.Characterization of gliomas: from morphology to molecules.Gliomatosis cerebri: no evidence for a separate brain tumor entity.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas.ATRX immunostaining predicts IDH and H3F3A status in gliomas.A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.Interactive phenotyping of large-scale histology imaging data with HistomicsML.The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.In vivo molecular profiling of human glioma using diffusion kurtosis imaging.Neurological update: gliomas and other primary brain tumours in adults.Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.Effect of Perfusion on Diffusion Kurtosis Imaging Estimates for In Vivo Assessment of Integrated 2016 WHO Glioma Grades : A Cross-Sectional Observational Study.Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging.Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.
P2860
Q31145092-4D82B43D-4A60-4069-8A6D-D17C4E9798A4Q33711322-489A1827-15C8-4006-9B05-87605398997CQ35869744-AFFB2E31-95B6-4693-8812-F0460635DC9AQ36402259-F870236C-A311-48E5-9262-B15891A6CCEFQ37160414-08F37E99-3721-489C-8E1D-39A6CEB03908Q37327761-6C5034AB-B5DC-46ED-A90A-92336401F6C6Q37339878-D2AFACBF-33E0-4AFC-8798-7FA8E0492556Q38390616-721168F0-1F70-4350-A39E-EE88584AFF9EQ38453759-2D0A8DE2-EAEB-40CE-8BEF-71BE28C28610Q38670567-5BEA960E-E68E-4014-8206-09823B274307Q38816272-76CB5799-32CC-4AAE-B25E-CF61E1ACB637Q38845657-4B641777-C36B-4CCA-B3B6-04796A4029B9Q38921975-9DCF1D50-D422-4810-8576-B9AAB6B9E6FFQ38931930-556787E8-5FE2-41C7-A066-0178761BC315Q38940482-2CBEBBB2-E892-4BDF-B795-5A6690CD87EFQ39091307-AC0EDC9D-8FD3-4390-9A90-2972824E03F5Q39159242-5DF1E7E8-303A-4F95-84F0-D8E5BA82DF83Q39412967-622A2E79-536F-46B2-83C4-DC32CF1CE41AQ40401765-C674FCCA-64BE-4F45-A98D-48432374B210Q40822804-F7D1F879-4159-49E6-B856-9785B0A9F6D0Q41472948-B191484F-FBB9-4577-B5A3-455A38B7362FQ41485878-F84DAD33-2D15-4B61-A635-E872615E05D1Q42683729-C9131FD0-A8BA-4862-B4A0-748841F6B878Q42701263-F4A54908-4472-4461-AD5F-19A44651CA25Q44457966-383808FD-5ED9-428F-BC7B-389C71FA6FF3Q45944097-22CD485C-8D40-423A-B8C5-6EDB2F1E55F4Q47316880-C8B34A6B-7315-4783-AEF2-0085E13033C3Q47393298-33F860C9-FDD2-42CC-A40A-E55682EA6035Q47583690-C5CAC10C-A383-4E72-8C88-09F336E3B5BAQ47592896-FAF15853-F71F-4760-98C3-0BD1417D3FADQ47720066-2E69A7EA-7A4D-41CF-BFA1-7F55A1DD2B97Q47771695-7105E3B6-AC5A-4EBC-BCA3-9563E0DFAA5AQ47943878-4CD08340-F99F-42C8-A554-3D9D8966CF0EQ47989137-3B5F5CA4-2DE3-416C-A72E-EC2D0096A122Q48025688-8160453A-A7AC-4564-9152-0E56E4540F3FQ48035299-07A1AA4F-25D5-4075-92BC-A177DC463C6BQ48134555-B60B0A25-D629-41BE-A4AF-B7B228EC0367Q48222832-F565C968-E3C1-4C08-A903-983A0401298FQ48523422-CF3F97AF-DD66-4142-B7E1-AD07ACB65FB2Q48663479-DACF3CDD-16A6-485A-BE43-5A4A329D0BD8
P2860
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@ast
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@en
type
label
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@ast
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@en
prefLabel
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@ast
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@en
P2093
P2860
P50
P1476
IDH mutant diffuse and anaplas ...... al: a grading problem for WHO.
@en
P2093
Adriana Olar
Andrey Korshunov
Annekathrin Kratz
Christian Hartmann
Christian Koelsche
David E Reuss
Jaap C Reijneveld
Kenneth Aldape
Pieter Wesseling
Yasin Mamatjan
P2860
P2888
P304
P356
10.1007/S00401-015-1438-8
P50
P577
2015-05-12T00:00:00Z